PepGen Stock Skyrockets 121% on Upgraded Analyst Outlook

Shares of PepGen (PEPG), a clinical-stage biotechnology company, soared an astonishing 121% in a dramatic trading session. The rally was fueled by a significant vote of confidence from Wall Street, as on the company and raised their price target to $12 from a previous $9.

The sudden surge was backed by immense investor interest, with trading volume exploding to nearly 125 million shares, a staggering 65 times its daily average. This wave of buying suggests a decisive shift in market sentiment for the company, which focuses on developing therapies for severe neuromuscular and neurological diseases like Duchenne muscular dystrophy.

The bullish analyst action represents a potential turning point for PepGen. The company has been navigating the challenging biotech landscape, including a previous clinical hold on its lead drug candidate, PGN-EDO51. Stifel's upgraded target indicates renewed optimism that the company's prospects may be clearing. This follows a period of recalibration, as the same firm had previously adjusted its price target down to $14 from $17 in early 2025, according to .

"The upgraded price target from a respected firm like Stifel is a major catalyst," noted one market analyst. "After facing clinical hurdles, such a strong signal of confidence can bring sidelined investors back into the fold and completely change the narrative around a developmental biotech stock."

For PepGen, the road ahead remains focused on its clinical pipeline. The is to advance its Enhanced Delivery Oligonucleotide (EDO) therapeutics. The market's enthusiastic response to the analyst rating suggests investors are now betting more heavily on a positive outcome for its ongoing and future trials. Investors will be closely watching for further data and regulatory updates on PGN-EDO51 and other programs as a key indicator of whether this rally has staying power.